|
2025
|
Invention
|
Tetrahydrofuran pyridone compound serving as nav1.8 inhibitor. The present invention provides a c... |
|
|
Invention
|
5-containing quinoline derivatives and use thereof as p2x7 antagonists. The present invention pro... |
|
|
Invention
|
Antibody targeting il-31ra or antigen-binding fragment thereof and use thereof. Disclosed are an ... |
|
|
Invention
|
Cyclic peptide containing carboxylic acid substitution against acinetobacter baumannii and use th... |
|
|
Invention
|
Mas-related g protein-coupled receptor x2 antagonist and use thereof. Provided in the present inv... |
|
|
Invention
|
Compounds targeting αvβ6 and use thereof. The present invention provides compounds targeting αvβ6... |
|
|
Invention
|
Targeting compound and use thereof. The present invention provides a targeting compound capable o... |
|
|
Invention
|
Fused ring compound as at2r agonist. Provided are a compound as shown in formula (IB), and a taut... |
|
2024
|
Invention
|
Targeting compound for use in delivery and use thereof. Disclosed in the present invention is a c... |
|
|
Invention
|
Solid dispersion of p2x3 receptor antagonist and preparation process thereof. Provided is a solid... |
|
|
Invention
|
Deuterated heterocyclic compound acting as pde4b inhibitor and use thereof. The present invention... |
|
|
Invention
|
Nav1.8 inhibitor compound, salt thereof, polymorph thereof, and use thereof. The present inventio... |
|
|
Invention
|
Mrgprx2 antagonist and use thereof. Provided in the present invention are a compound as shown in ... |
|
|
Invention
|
Bicyclic tead inhibitor. 0 0 ) of the invention, and can be used for preventing and/or treating d... |
|
|
Invention
|
Heterocyclic ring-containing tead inhibitor. A heterocyclic ring-containing TEAD inhibitor, which... |
|
|
Invention
|
Salt and crystal form of kif18a inhibitor compound, preparation method therefor and use thereof. ... |
|
|
Invention
|
At2r antagonist and use thereof. The present invention provides a compound as shown in formula I.... |
|
|
Invention
|
Cyclopeptide of acinetobacter baumannii and use thereof. A cyclopeptide of Acinetobacter baumanni... |
|
|
Invention
|
Thienylsulfonyl carbamates as at2r agonists. Compounds represented by the following structure, or... |
|
|
Invention
|
Compound acting as mrgprx2 antagonist, and preparation method therefor and use thereof. Provided ... |
|
|
Invention
|
Thiophene sulfonyl carbamate as at2r agonist, and use thereof. Provided are a compound represente... |
|
|
Invention
|
Fluoroimidazopyridine compound as irak4 degradation agent and use thereof. The present invention ... |
|
|
Invention
|
Crystal forms of tubulin-src dual-targeting inhibitor, preparation method therefor and use thereo... |
|
|
Invention
|
Heterocyclic compound as at2r antagonist and use thereof. The present invention provides a compou... |
|
|
Invention
|
A receptor modulator and use thereof. AA receptor, |
|
|
Invention
|
A receptor regulator. AA receptor. |
|
|
Invention
|
Composition containing btk inhibitor, and use thereof. A composition containing a BTK inhibitor, ... |
|
|
Invention
|
Use of btk inhibitor and single dose drug. A use of a compound represented by formula (I) or a st... |
|
|
Invention
|
Crystal form of heterocyclic compound, salt thereof, crystal form of salt thereof, and use. Discl... |
|
|
Invention
|
Anti-fgfr2b monoclonal antibody. Provided is an anti-FGFR2Ⅲb antibody. Specifically, the anti-FGF... |
|
|
Invention
|
Substituted tetrahydrofurans as nav1.8 inhibitors. Provided in the present invention are compound... |
|
|
Invention
|
Heterocyclic compound as at2r antagonist. The present invention provides a compound as shown in f... |
|
|
Invention
|
Kif18a inhibiting compound and use thereof. The present invention provides a compound as represen... |
|
|
Invention
|
Sulfoxide compound and use thereof. Disclosed in the present invention are a sulfoxide compound a... |
|
|
Invention
|
Modified peptide as trem-1 inhibitor. Provided in the present invention is a TLT-1 derived peptid... |
|
2023
|
Invention
|
Method for preparing p2x3 inhibitor. 222 to a coupling reaction to obtain 1D; subjecting the comp... |
|
|
Invention
|
Ep2 and ep4 receptor antagonist. The present invention provides an EP2 and EP4 receptor antagonis... |
|
|
Invention
|
Amide compound as nav1.8 inhibitor. The present invention provides a compound represented by form... |
|
|
Invention
|
Compound for inhibiting 15-pgdh and use thereof. The present invention provides a heterocyclic co... |
|
|
Invention
|
15-pgdh inhibitor. A heterocyclic compound represented by formula I, a solvate thereof, a pharmac... |
|
|
Invention
|
Tead inhibitor. The present invention provides a compound represented by formula I, and a tautome... |
|
|
Invention
|
Imidazopyridine compound as irak4 degradation agent and use thereof. An imidazopyridine compound ... |
|
|
Invention
|
Kif18a inhibitor and use thereof.
The present invention provides a heterocyclic compound as repr... |
|
|
Invention
|
At2r agonist.
The present disclosure relates to the field of medicine. Specifically, provided in... |
|
|
Invention
|
P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof.
The present invention ... |
|
|
Invention
|
Diaryl compound as tubulin/src dual target inhibitor.
The present invention provides a diaryl co... |
|
2022
|
Invention
|
15-pgdh inhibitor and use thereof.
Provided are a 15-PGDH inhibitor and the use thereof. The 15-... |
|
|
Invention
|
Ep4 antagonist compound as well as salt, polymorph and use thereof.
An EP4 antagonist represente... |
|
|
Invention
|
Tricyclic compound used as gpr84 antagonist.
The present invention relates to a tricyclic compou... |
|
|
Invention
|
Pyridopyrimidinone derivative, preparation method therefor, and use thereof.
A pyridopyrimidinon... |
